Compare GSK plc (GSK) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Standard Lithium Ltd — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Standard Lithium Ltd trades at $2.43 (market cap $604.50M). The key difference: GSK plc is far larger — about 169.7× Standard Lithium Ltd's market cap, and GSK plc pays a 3.57% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| GSK | SLI | |
|---|---|---|
Market Cap | $102.60B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $5.65 |
52-Week Low | $38.22 | $1.93 |
Enterprise Value | $123.04B | $467.42M |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
SLI trades at $2.41, down 4.74% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $48.40M in 2025, with negative ROE and ROA, but beat EPS estimates in two recent quarters. Positive news includes a $225M DOE grant and progress on its South West Arkansas lithium project, with institutional buying from Amundi (64.9% stake increase in Q1 2026 per SEC filing).
The outlook hinges on project execution, as SLI transitions to production with strong analyst support (100% buy ratings). Key risks include cash burn from negative operating cash flow and reliance on financing, but de-risking milestones and government backing offer upside if timelines are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
